A systematic review of 10 studies covering 6,623 non-diabetic overweight or obese participants confirmed semaglutide is a highly effective weight loss agent across different doses and forms.
6,623 non-diabetic patients studiedAcross 10 high-quality studies, semaglutide consistently produced significant weight and waist circumference reductions in people without diabetes
What the researchers found
Across 10 studies (9 RCTs and 1 retrospective cohort) encompassing 6,623 non-diabetic overweight or obese participants, semaglutide in various doses and forms demonstrated consistent, significant weight loss effects. The review examined changes in body weight, waist circumference, and the proportion of patients achieving at least 5% clinically meaningful weight loss. The consolidated evidence endorsed semaglutide as a highly efficient weight-reducing agent in people without diabetes.
Why it matters
Most early GLP-1 RA research focused on diabetes patients, where weight loss was initially considered a side benefit. This systematic review consolidates the evidence specifically for non-diabetic populations — the primary market for drugs like Wegovy. By pooling results from 6,623 participants across high-quality studies, it provides a comprehensive evidence base supporting semaglutide's use purely as a weight loss treatment.
The numbers in context
10 studies · 9 RCTs + 1 retrospective cohort · 6,623 participants · Non-diabetic population · Endpoints: weight change, waist circumference, ≥5% weight loss achievement
How the study worked
Systematic review following PRISMA 2020 guidelines. Three databases searched (PubMed, PubMed Central, Cochrane Library) with 423 initial papers narrowed to 10 high-quality studies published in the last 5 years. Studies were filtered using inclusion/exclusion criteria and quality appraisal tools. Included studies compared semaglutide at various doses and forms to placebo or active comparators in non-diabetic overweight/obese adults.
What this study cannot tell us
This is a systematic review without meta-analysis — the results are described qualitatively rather than pooled statistically. Published in Cureus (a lower-impact journal), and the abstract doesn't report specific weight loss numbers, making it difficult to assess the magnitude of effects. The review's conclusion is broad ('highly efficient') without distinguishing between dose-specific outcomes. Only studies from the last 5 years were included, potentially missing earlier relevant data.
How to read the evidence
This is a systematic review of mostly RCTs following PRISMA guidelines, representing a high level of evidence synthesis. However, it describes findings qualitatively rather than performing a meta-analysis, and specific weight loss numbers are not reported in the abstract.
When this study was published
Published in 2024 covering studies from the previous 5 years. This captures the STEP trial era and other pivotal semaglutide weight loss studies. Newer data on higher doses and longer follow-up may have been published since.
The bigger picture
This review captures the evidence supporting semaglutide's transition from a diabetes drug to a mainstream weight loss treatment. With Wegovy (semaglutide 2.4 mg) now prescribed to millions of non-diabetic patients, consolidating the efficacy evidence for this specific population is important for clinical practice. The review arrives as the obesity drug market is projected to reach $100+ billion and as debate continues about insurance coverage, access, and long-term use.
Questions still open
- Does semaglutide's weight loss efficacy differ between oral and injectable forms in non-diabetic populations?
- What is the optimal dose for non-diabetic patients balancing weight loss efficacy against side effects?
- How does semaglutide compare to tirzepatide specifically in non-diabetic obese populations?
Common questions
How much weight can non-diabetic people lose on semaglutide?
Does semaglutide work differently for weight loss in people with vs. without diabetes?
Read the original research
Efficacy of Different Doses and Forms of the GLP-1 Receptor Agonist Semaglutide in Weight Reduction Among Non-diabetic Obese or Overweight Populations.
Cureus, 16(9), e68786
Citation
Fatima, Nazeefa; Anand, Abhinav; Palvia, Aadi R; Kaur, Avneet; Azeez, Gibran A; Thirunagari, Mounika; Butt, Samia Rauf R. (2024). Efficacy of Different Doses and Forms of the GLP-1 Receptor Agonist Semaglutide in Weight Reduction Among Non-diabetic Obese or Overweight Populations.. Cureus, 16(9), e68786. https://doi.org/10.7759/cureus.68786